Prevalence and correlates of HPV among women attending family-planning clinics in Thailand

BMC Infectious Diseases

David D Celentano⁵  Patti E Gravitt⁵  Somchai Sriplienchan¹  Sungwal Rugpao¹  Charoen Vipupinyo⁷  Pissamai Yuenyao⁸  Virach Wootipoom³  Chailert Phongnarisorn²  Esther Kim⁵  Amha Tadesse⁶  Kai-Li Liaw⁴  Swati Gupta⁴  Morgan A Marks⁵ 

[1]Research Institute for Health Sciences, Chiang Mai, Thailand

[2]Chiang Mai University, Chiang Mai, Thailand

[3]Prince of Songkla University, Songkla, Thailand

[4]Merck Research Laboratories, West Point, PA, USA

[5]Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

[6]PRA Health Sciences, Fort Washington, PA, USA

[7]Rajavithi Hospital, Bangkok, Thailand

[8]Khon Kaen University, Khon Kaen, Thailand

关键词: CIN;    Thailand;    Epidemiology;    HPV;   

Others  :  1173926
DOI  :  10.1186/s12879-015-0886-z

 received in 2014-12-11, accepted in 2015-03-12,  发布年份 2015

【 摘 要 】

Background

Cervical cancer is the most common cancer among women of reproductive age in Thailand. However, information on the prevalence and correlates of anogenital HPV infection in Thailand is sparse.

Methods

HPV genotype information, reproductive factors, sexual behavior, other STI and clinical information, and cervical cytology and histology were assessed at enrollment among one thousand two hundred and fifty-six (n = 1,256) HIV negative women aged 20–37 from Thailand enrolled in a prospective study of the natural history of HPV. The type-specific prevalence of HPV was estimated using cervical swab specimens from healthy women and women with a diagnosis of CIN 2/3 at baseline. Prevalence ratios (95% CI) were estimated using Poisson regression to quantify the association of demographic, behavioral, and clinical correlates with prevalent HPV infection.

Results

Overall, 307 (24.6%) and 175 (14.0%) of women were positive for any HPV type and any HR-HPV type, respectively; the most common types were 72, 52, 62, and 16. Among women diagnosed with CIN 2/3 at enrollment (n = 11), the most prevalent HPV types were 52 and 16. In multivariate analysis, HPV prevalence at enrollment was higher among women with: long-term combined oral contraceptive use, a higher number of lifetime sexual partners, a prior Chlamydia infection, and a current diagnosis of Bacterial Vaginosis.

Conclusion

The study findings provide important information that can be used in the evaluation of primary and secondary interventions designed to reduce the burden of cervical cancer in Thailand.

【 授权许可】

   
2015 Marks et al.; licensee BioMed Central.

【 参考文献 】

• [1]Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F: Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013, 49(15):3262-73.
• [2]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-9.
• [3]Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3:S1-S10.
• [4]Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88(1):63-73.
• [5]Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al.: Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003, 187(8):1246-56.
• [6]Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al.: Hormonal contraception and the risk of HIV acquisition. Aids 2007, 21(1):85-95.
• [7]Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al.: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287(16):2114-9.
• [8]Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al.: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-61.
• [9]Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, et al.: Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002, 40(3):902-7.
• [10]Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-27.
• [11]Thompson ML, Myers JE, Kriebel D: Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med 1998, 55(4):272-7.
• [12]Chansaenroj J, Junyangdikul P, Chinchai T, Swangvaree S, Karalak A, Gemma N, et al.: Large scale study of HPV genotypes in cervical cancer and different cytological cervical specimens in Thailand. J Med Virol 2014, 86(4):601-07.
• [13]Wongworapat K, Keawvichit R, Sirirojn B, Dokuta S, Ruangyuttikarn C, Sriplienchan S, et al.: Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. Sex Transm Dis 2008, 35(2):172-3.
• [14]Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-8.
• [15]Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al.: Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-9.
• [16]Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al.: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-59.
• [17]Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al.: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case–control study. Lancet 2002, 359(9312):1085-92.
• [18]Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, Munoz J, et al. HPV and Cervical Cancer in the World 2007 report. Vaccine. 2007;25(Supplement 3):C198.
• [19]Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al.: Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997, 6(10):799-805.
• [20]Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, et al.: Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991, 83(14):997-1003.
• [21]Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, et al.: The association of hormonal contraceptive use and HPV prevalence. Int J Cancer 2011, 128(12):2962-70.
• [22]Marks M, Gravitt PE, Gupta SB, Liaw KL, Tadesse A, Kim E, et al.: Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis 2011, 204(10):1505-13.
• [23]Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(3):218-26.
• [24]Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al.: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285(23):2995-3002.
• [25]Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee SK, et al.: Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008, 198(7):971-8.
• [26]Munoz N, Hernandez-Suarez G, Mendez F, Molano M, Posso H, Moreno V, et al.: Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009, 100(7):1184-90.
• [27]Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, et al.: A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002, 94(18):1406-14.
• [28]Castle PE, Walker JL, Schiffman M, Wheeler CM: Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 2005, 117(6):1007-12.
• [29]Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al.: Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case–control study nested within the Manchester cohort. Br J Cancer 2000, 83(11):1565-72.
• [30]Marks M, Klein S, Gravitt P: Hormonal contraception and HPV: a tale of differing and overlapping mechanisms. Contraception. 2011, 2:161-74.
• [31]Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, et al.: Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005, 191(7):1129-39.
• [32]Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, et al.: A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis 2012, 12:33. BioMed Central Full Text
• [33]Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, et al.: Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005, 162(7):668-75.